Top 20 Global Pharmaceutical Company Signs $1.9 Million Software and Services Agreement With eResearchTechnology
eResearchTechnology, Inc. (eRT), (Nasdaq: ERES – News), a leading e-research technology and services provider, announced today that it has entered into an agreement valued at more than $1.9 million to provide a top-twenty global pharmaceutical company with an integrated technology and services solution that includes an end-to-end clinical research platform, electronic data capture (EDC), and a web portal for access to real-time data.
The integrated software and technology that eRT will provide to this leading drug developer will include its eResearch Network, Enterprise EDC platform and eResearch Community web portal. eRT’s eResearch Network suite features applications for clinical data management, trial management and monitoring, and adverse event management and reporting. In combination with eRT’s Enterprise EDC solution, the sponsor will deploy the eResearch Community web portal for overall command and control, real-time analysis and decision support, and collaboration and communications across its clinical research network.
In addition to technology licenses and maintenance, the agreement leverages eRT’s full range of services, including:
- Regulatory compliant hosting
- Configuration and implementation an initial EDC study
- Custom-designed EDC site support services
- eHealth Education web-based training
- Technology transfer services
- Packaged kits and associated services to ensure effective system validation and development of standard operating procedures
“We are delighted that, after an extensive evaluation, this leading global drug developer has selected eRT to provide and implement a comprehensive end- to-end clinical research platform based around eRT’s Enterprise EDC and eResearch Community solutions,” said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. “As forward thinking top pharmaceutical organizations seek to extend the impact of EDC and related technologies across the enterprise, eRT’s comprehensive platform of end-to-end technology and services is distinguished in its ability to address the complex demands associated with effective implementation and change management.”
Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.eRT.com ) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company’s financial results can be found in the company’s Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission.
